Ken Griffin Bicycle Therapeutics PLC Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 4,100 shares of BCYC stock, worth $46,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,100

Previous 11,600 64.66%

Holding current value

$46,125

Previous $263,000 78.33%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$13.81 - $27.5 $572,852 - $1.14 Million	41,481 Added 40.37%	144,230 $2.02 Million
Q3 2024 Nov 14, 2024	SELL	$19.58 - $27.24 $1.56 Million - $2.17 Million	-79,566 Reduced 43.64%	102,749 $2.33 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $24.69 $2.46 Million - $3.03 Million	122,875 Added 206.72%	182,315 $3.69 Million
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $3.94 Million - $6.13 Million	-235,025 Reduced 79.81%	59,440 $1.48 Million
Q4 2023 Feb 14, 2024	BUY	$13.29 - $22.2 $2.11 Million - $3.52 Million	158,768 Added 117.0%	294,465 $5.32 Million
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $488,365 - $644,201	24,541 Added 22.08%	135,697 $2.73 Million
Q2 2023 Aug 14, 2023	BUY	$18.95 - $28.67 $832,966 - $1.26 Million	43,956 Added 65.41%	111,156 $2.84 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $684,884 - $1.07 Million	34,210 Added 103.7%	67,200 $1.43 Million
Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $313,983 - $507,120	-15,414 Reduced 31.84%	32,990 $976,000
Q3 2022 Nov 14, 2022	SELL	$17.49 - $28.44 $3.41 Million - $5.54 Million	-194,930 Reduced 80.11%	48,404 $1.13 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $2.4 Million - $8.7 Million	185,147 Added 318.19%	243,334 $4.08 Million
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $1.37 Million - $2.01 Million	32,840 Added 129.56%	58,187 $3.54 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $708,448 - $1.12 Million	25,347 New	25,347 $1.05 Million
Q1 2021 May 17, 2021	SELL	$19.12 - $30.25 $555,149 - $878,308	-29,035 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$17.95 - $21.36 $521,178 - $620,187	29,035 New	29,035 $521,000

Others Institutions Holding BCYC

# of Institutions

104

Shares Held

42.9M

Call Options Held

12.1K

Put Options Held

17.4K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $334M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account